BPC-157 resists enzymatic breakdown which is precisely why oral delivery is a meaningful research variable for this compound, not a theoretical one.2 But that stability does not mean every delivery route produces the same result
However, they can also grow due to poor harvesting practices, improper storage, and less-than-optimal conditions during processing and transportation
Some patients may notice mild soreness at the injection site, but this is temporary and resolves quickly
How you access them matters
The goal is achieving systemic peptide levels comparable to established injectable protocols while accounting for the lower absorption efficiency of nasal delivery
At minimum: Outcomes Weight trend (weekly average) Waist circumference Body composition if available (DEXA, BIA with consistency) Strength markers (basic lifts, grip strength, functional tests) Safety Blood pressure + resting HR A1c and fasting glucose (more often if diabetes) CMP (liver/kidney) Lipids (periodic) If manipulating GH/IGF-1 signaling: IGF-1 (and clinical context matters) Stop criteria Persistent tachycardia, edema, severe fatigue, worsening glycemia, abnormal labs, or new symptoms you cant explain The what to ask your clinic questions (high signal, low fluff) If a clinic recommends a peptide stack, ask: What is the problem were solving, in one sentence
